Skip to content
PEPLUX

BPC-157 in an oral capsule format

BPC-157 Capsules

Also called Body Protection Compound-157.

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Oral use

The process

Licensed provider review

BPC-157 Capsules cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 13, 2026

BPC-157 Capsules is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is BPC-157 Capsules?

BPC-157 in an oral capsule. The dispensing pharmacy must document its identity, salt form and formulation before ordering is enabled.

Adults seeking a provider discussion about oral BPC-157 after reading its evidence limitations and risks. Choosing an oral format does not establish that it is safe or effective.

Key risks

  • Safety in people has not been established. Side effects, interactions and longer-term risks of oral BPC-157 are not adequately characterized.
  • Immune or allergic reactions to a peptide or an ingredient are possible. An oral format does not remove these concerns.
All risks and who should not use it

FDA status

FDA status for BPC-157 Capsules.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

BPC-157 Capsules is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

An FDA advisory committee recommendation is not a listing. Nothing changes unless FDA publishes a final rule.

BPC-157 Capsules

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

FDA’s documents list it as BPC-157.

BPC-157 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule.

Basis
FDA's 503A categories document of April 15, 2026 announced the removal of BPC-157 from Category 2, effective seven days later, because its nominations were withdrawn. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page says compounded BPC-157 may pose a risk of immunogenicity and that FDA has identified no, or only limited, safety-related information for the proposed routes of administration.
Checked on
October 13, 2026

How it works

BPC-157 Capsules mechanism.

BPC-157 is a synthetic peptide of 15 amino acids. This listing concerns an oral capsule format. How much of an oral formulation reaches the circulation and how it behaves in people depend on the formulation and have not been established for this product.

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

BPC-157 Capsules: evidence and limitations.

The research on BPC-157 is largely in laboratory and animal models. Published human evidence is limited, and evidence from another formulation or route cannot be assumed to apply to an oral capsule. No benefit for this product has been established by the information presented here.

Risks

BPC-157 Capsules risks and side effects.

  • Safety in people has not been established. Side effects, interactions and longer-term risks of oral BPC-157 are not adequately characterized.
  • Immune or allergic reactions to a peptide or an ingredient are possible. An oral format does not remove these concerns.
  • How this formulation is absorbed and how food, medicines or supplements affect it have not been established.
  • Safety information is insufficient for use during pregnancy or breastfeeding or in people under 18. These groups should not use this product.
  • Seek urgent medical care for trouble breathing, swelling of the face or throat, or other signs of a serious allergic reaction.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • The exact capsule ingredients and formulation, including any inactive ingredients or allergens

  • All medicines, supplements, current conditions and any prior allergic or immune reaction

  • The limited evidence for this oral product and whether an established treatment should be considered first

  • Pregnancy, breastfeeding, plans to conceive and any applicable anti-doping rules

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Microbial limits

Sport and anti-doping

Prohibited under the WADA code.

  • Prohibited at all times under WADA class S0 (non-approved substances).

If you compete under an anti-doping authority, or are tested through your employer or federation, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.

Straight answers

Common questions about BPC-157 Capsules.

What is the FDA status of BPC-157 Capsules?
No compounding pathway today. An FDA advisory committee recommendation is not a listing. BPC-157 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule. Checked against primary sources on October 13, 2026.
Is compounded BPC-157 Capsules an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. BPC-157 Capsules is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for BPC-157 Capsules, and what does it not?
The research on BPC-157 is largely in laboratory and animal models. Published human evidence is limited, and evidence from another formulation or route cannot be assumed to apply to an oral capsule. No benefit for this product has been established by the information presented here.
What are the risks of BPC-157 Capsules?
Safety in people has not been established. Side effects, interactions and longer-term risks of oral BPC-157 are not adequately characterized. The full list of side effects, and of who should not use BPC-157 Capsules, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Does BPC-157 Capsules require baseline labs?
Your prescriber determines whether baseline labs are needed before considering BPC-157 Capsules. Baseline labs are included in the price.
What does BPC-157 Capsules cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is BPC-157 Capsules prohibited in sport?
Prohibited at all times under WADA class S0 (non-approved substances). If you are subject to anti-doping testing, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.
How is BPC-157 Capsules given?
Oral use. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

BPC-157 Capsules is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker